Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom

ConclusionUse of CT-P13 SC may lead to substantial cost savings for the UK society.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research